JP2024536600A - ブタａ型インフルエンザウイルス感染に対して子ブタを防御するためのワクチン - Google Patents

ブタａ型インフルエンザウイルス感染に対して子ブタを防御するためのワクチン Download PDF

Info

Publication number
JP2024536600A
JP2024536600A JP2024524385A JP2024524385A JP2024536600A JP 2024536600 A JP2024536600 A JP 2024536600A JP 2024524385 A JP2024524385 A JP 2024524385A JP 2024524385 A JP2024524385 A JP 2024524385A JP 2024536600 A JP2024536600 A JP 2024536600A
Authority
JP
Japan
Prior art keywords
vaccine
iav
antigen
αrp
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024524385A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024536600A5 (OSRAM
Inventor
ナガラジ，バサヴ・ハンガラプラ
モグラ－，マーク・エー
セーゲルス，ルード・フィリップ・アントゥーン・マリア
Original Assignee
インターベット インターナショナル ベー． フェー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インターベット インターナショナル ベー． フェー． filed Critical インターベット インターナショナル ベー． フェー．
Publication of JP2024536600A publication Critical patent/JP2024536600A/ja
Publication of JP2024536600A5 publication Critical patent/JP2024536600A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2024524385A 2021-10-25 2022-10-24 ブタａ型インフルエンザウイルス感染に対して子ブタを防御するためのワクチン Pending JP2024536600A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21204364.0 2021-10-25
EP21204364 2021-10-25
PCT/EP2022/079532 WO2023072805A1 (en) 2021-10-25 2022-10-24 A vaccine for the protection of piglets against swine influenza a virus infection

Publications (2)

Publication Number Publication Date
JP2024536600A true JP2024536600A (ja) 2024-10-04
JP2024536600A5 JP2024536600A5 (OSRAM) 2025-10-24

Family

ID=78617136

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024524385A Pending JP2024536600A (ja) 2021-10-25 2022-10-24 ブタａ型インフルエンザウイルス感染に対して子ブタを防御するためのワクチン

Country Status (5)

Country Link
US (1) US20250281597A1 (OSRAM)
EP (1) EP4422678A1 (OSRAM)
JP (1) JP2024536600A (OSRAM)
CN (1) CN118139640A (OSRAM)
WO (1) WO2023072805A1 (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021255225A1 (en) * 2020-06-19 2021-12-23 Intervet International B.V. Swine influenza a virus vaccine comprising a nucleic acid construct comprising first, second and third nucleic acid sequences encoding distinct neuraminidase antigens of the virus

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69015222T2 (de) 1989-02-04 1995-05-04 Akzo Nv Tocole als Impfstoffadjuvans.
ES2321212T3 (es) 2004-05-18 2009-06-03 Alphavax, Inc. Vectores alfavirus derivados de tc-83, particulas y metodos antecentes de la invencion.
DK2183368T3 (en) 2007-06-21 2016-09-05 Alphavax Inc PROMOTER-FREE CASES FOR EXPRESSION OF ALPHAVIRUS STRUCTURE PROTEINS
TWI551295B (zh) 2008-04-18 2016-10-01 英特威特國際股份有限公司 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）用疫苗
WO2017087492A1 (en) * 2015-11-16 2017-05-26 Kansas State University Research Foundation Influenza virus vaccine and vaccine platform
JP6931059B2 (ja) 2016-12-23 2021-09-01 インターベット インターナショナル ベー． フェー． 豚用混合ワクチン
MX2020005584A (es) 2017-12-04 2020-09-14 Intervet Int Bv Vacunacion con particulas de replicon y adyuvante oleoso.
US12290556B2 (en) 2017-12-18 2025-05-06 Intervet Inc. Swine influenza a virus vaccine
US20230277649A1 (en) * 2020-06-19 2023-09-07 Intervet Inc. Swine influenza a virus vaccine comprising two distinct rna replicon particles

Also Published As

Publication number Publication date
CN118139640A (zh) 2024-06-04
US20250281597A1 (en) 2025-09-11
EP4422678A1 (en) 2024-09-04
WO2023072805A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
Tizard Vaccination against coronaviruses in domestic animals
Lee et al. A review of vaccine development and research for industry animals in Korea
Crawford et al. Status of vaccines for porcine epidemic diarrhea virus in the United States and Canada
TWI619812B (zh) 豬流行性下痢病毒品系及得自其之免疫組成物
JP7346417B2 (ja) ブタインフルエンザａウイルスワクチン
CN111447948B (zh) 具有复制子颗粒和油佐剂的疫苗
Opriessnig et al. Future perspectives on swine viral vaccines: where are we headed?
JP7174698B2 (ja) ブタワクチン
JP2020502080A (ja) 弱毒ブタインフルエンザワクチン並びにその作製および使用方法
US20250281597A1 (en) A vaccine for the protection of piglets against swine influenza a virus infection
CN115697398A (zh) 包含两种不同rna复制子颗粒的甲型猪流感病毒疫苗
JP7513614B2 (ja) プライム－ブーストワクチン接種レジメン
JP7754855B2 (ja) ウイルスの別々のノイラミニダーゼ抗原をエンコードする第１、第２および第３の核酸配列を含む核酸構築物を含むブタインフルエンザａウイルスワクチン
RU2817873C2 (ru) Схема вакцинации "прайм-буст"
RU2780233C2 (ru) Способ профилактического лечения свиней
CN115836082A (zh) 包含编码特定病毒谱系抗原的核酸构建体的甲型猪流感病毒疫苗
BR122025027501A2 (pt) Vacina com partículas de replicon e adjuvante de óleo, kit, uso e partícula de replicon de rna de alfavírus de encefalite equina venezuelana (vee) que codifica um antígeno originário de um patógeno de animal

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251016